Findings

What do systematic reviews say?

76 questions · 113 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 23 · 20.4%GRADE not reported 6 · 5.3%Very low 15 · 13.3%Low 10 · 8.8%Moderate 42 · 37.2%High 17 · 15%

BoNT‐A vs sham

Spasticity (ankle plantarflexors) · children with CP

3 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 156 participants
Moderate
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 144 participants
Moderate
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Moderate

BoNT‐A vs sham

Adverse events · children with CP

BoNT‐A showed no clear difference in adverse events compared with placebo or sham (moderate certainty).

3 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
RR 1.29 [0.87, 1.93]
12 studies · 918 participants
Moderate
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BoNT‐A vs sham

Instrumented gait analysis (kinematics) (not measured) · children with CP

The review found no eligible studies for this question.

2 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BoNT‐A vs sham

Gait assessment ‐ not measured · children with CP

The review found no eligible studies for this question.

1 finding from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BoNT‐A vs serial casting

Instrumented gait analysis (peak ankle dorsiflexion in stance) · children with CP

3 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Low
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 61 participants
Low
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Moderate

BoNT‐A vs serial casting

Observational gait analysis · children with CP

3 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Moderate
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Moderate
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Moderate

BoNT‐A vs serial casting

Function · children with CP

3 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Moderate
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 41 participants
Moderate
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Moderate

BoNT‐A vs serial casting

Change in ankle dorsiflexion range of motion Lidcome Template in degrees. Scale from: 0.36 to 31.28. · children with CP

1 finding from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Low

BoNT‐A vs serial casting

Satisfaction (not measured) · children with CP

The review found no eligible studies for this question.

3 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BoNT‐A vs serial casting

Spasticity (ankle plantarflexors) · children with CP

3 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Low
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 67 participants
Low
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 44 participants
Low

BoNT‐A vs serial casting

Adverse events · children with CP

BoNT‐A showed no clear difference in adverse events compared with serial casting (low certainty).

3 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
RR 0.59 [0.03, 11.03]
3 studies · 64 participants
Low
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BoNT‐A vs serial casting

Range of motion (passive ankle dorsiflexion) · children with CP

2 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 67 participants
Low
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 44 participants
Low

BoNT‐A vs orthoses

Instrumented gait analysis (not reported) · children with CP

The review found no eligible studies for this question.

1 finding from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BoNT‐A vs orthoses

Observational gait analysis (not reported) · children with CP

The review found no eligible studies for this question.

1 finding from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BoNT‐A vs orthoses

Function · children with CP

1 finding from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Very low

BoNT‐A vs orthoses

Range of motion (passive hip abduction) · children with CP

1 finding from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Very low

BoNT‐A vs orthoses

Satisfaction (not reported) · children with CP

The review found no eligible studies for this question.

1 finding from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BoNT‐A vs orthoses

Spasticity (hip adductors) · children with CP

1 finding from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Very low

BoNT‐A vs orthoses

Adverse events (not reported) · children with CP

The review found no eligible studies for this question.

1 finding from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BoNT‐A vs usual care or physiotherapy

Observational gait analysis · children with CP

1 finding from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Very low